证券代码：688136 证券简称：科兴制药 公告编号：2025-086 科兴生物制药股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 至2025 年 10 月 17 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 股东会召开日期：2025年10月17日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期、时间和地点 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 2025年第二次临时股东会 召开日期时间：2025 年 10 月 17 日 14 点 00 分 召开地点：深圳市南山区高新中一道与科技中一路交汇处创益科技 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-080 科兴生物制药股份有限公司 第三届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 科兴生物制药股份有限公司（以下简称"公司"）第三届董事会第二次会议 于 2025 年 9 月 29 日在深圳市南山区创益科技大厦 B 栋 19 楼会议室以现场结合 通讯的方式召开。本次会议通知于 2025 年 9 月 26 日通过邮件的方式送达各位董 事。本次会议应出席董事 8 人，实际出席董事 8 人。 会议由董事长邓学勤主持，部分高管列席会议。会议召开符合有关法律、法 规、规章和《公司章程》的规定，会议决议合法、有效。 二、董事会会议审议情况 经各位董事认真审议，会议形成了如下决议： （一）审议通过《关于公司发行 H 股股票并在香港联合交易所有限公司上市 的议案》 为深化公司"创新+国际化"的战略布局，加快海外业务发展，进一步提高 公司综合竞争力及国际品牌形象，同时充分借助国际资本市场的资源与机制优势， 优化资本结构，拓 ...

人民财讯9月30日电，科兴制药(688136)9月30日公告，公司拟发行H股股票并在香港联合交易所有限公 司主板挂牌上市。 ...

Market Overview - The major indices in the A-share market experienced an upward trend, with the Shanghai Composite Index rising by 0.90% to close at 3862.53 points, and the Shenzhen Component Index increasing by 2.05% to 13479.43 points [1][8] - The overall market saw a total trading volume of 21781.43 billion, which is an increase of 120.35 billion compared to the previous trading day [9] Economic Insights - The Central Committee of the Communist Party of China held a meeting on September 29 to discuss the 15th Five-Year Plan, indicating a focus on economic and social development [16][18] - The People's Bank of China conducted a 2886 billion yuan reverse repurchase operation with a fixed interest rate of 1.40%, resulting in a net injection of 481 billion yuan into the market [20] Industry Dynamics - The Ministry of Industry and Information Technology, along with other departments, issued the "Nonferrous Metals Industry Stabilization Growth Work Plan (2025-2026)", projecting an average annual growth of 5% in the industry value added [27][28] - The "Petrochemical Industry Stabilization Growth Work Plan (2025-2026)" was also released, aiming for an average annual growth of over 5% in the industry value added [30][32] Company Updates - Laiyifen (603777.SH) announced a third employee stock ownership plan, targeting key management personnel of its subsidiary, with a share price set at 6.91 yuan per share [37] - Bright Dairy (600597.SH) plans to sell its New Zealand North Island assets for approximately 1.7 billion USD, which is expected to improve its net profit by 10 to 15 million NZD in the 2026 fiscal year [41][42] - Sinovac Biotech (688136.SH) received acceptance for its clinical trial application for the GB10 injection, aimed at treating serious eye diseases [43] - China CRRC (601766.SH) launched several brand cultural achievements to enhance its brand value and technological capabilities [45]

Core Viewpoint - The acceptance of the clinical trial application for GB10 injection marks a significant milestone in the company's innovative drug development process, indicating progress in its dual-target antibody research strategy [3]. Group 1: Product Information - Product Name: GB10 Injection [2] - Application Type: Clinical trial registration for domestic drug production [2] - Indications: Treatment of age-related macular degeneration (nAMD) and diabetic macular edema (DME) [2] - Dosage Form: Injection [2] - Product Overview: GB10 injection is a high-concentration ophthalmic injection developed by Shenzhen Kexing, targeting both VEGF and Ang-2, with preclinical data showing efficacy comparable to international competitors [2]. Group 2: Impact on the Company - The acceptance of the clinical trial application is a crucial step in the company's drug development, potentially enhancing its product portfolio and market competitiveness if the drug successfully reaches the market [3].

（编辑 任世碧） 证券日报网讯 9月29日晚间，科兴制药发布公告称，近日，公司全资子公司深圳科兴药业有限公司收到 国家药品监督管理局行政许可文书《受理通知书》，公司申报的"GB10注射液"临床试验申请已获得受 理。 ...

Core Viewpoint - The acceptance of the clinical trial application for "GB10 Injection" by the National Medical Products Administration marks a significant advancement in the company's innovative drug development process [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., has received the acceptance notice for the clinical trial application of "GB10 Injection" [1] - This acceptance is a crucial step in the company's dual-antibody research and development strategy based on its proprietary technology platform [1] Group 2: Market Implications - Successful development and future market launch of the drug could provide a more diverse product offering to meet market demand [1] - This development is expected to enrich the company's product portfolio and enhance its market competitiveness [1]

证券代码：688136 证券简称：科兴制药 公告编号：2025-079 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，科兴生物制药股份有限公司（以下简称"公司"）全资子公司深圳科 兴药业有限公司（以下简称"深圳科兴"）收到国家药品监督管理局（以下简称 "国家药监局"）行政许可文书《受理通知书》，公司申报的"GB10注射液"临 床试验申请已获得受理。 现将相关情况公告如下： 一、 申请注册药品的基本情况 1、产品名称：GB10 注射液 2、申请事项：境内生产药品注册临床试验 3、受理号：CXSL2500841 科兴生物制药股份有限公司 自愿披露关于 GB10 注射液临床试验注册申请获得受理的公告 GB 10 注射液是深圳科兴自主研发、拥有全球知识产权的抗 VEGF/Ang-2 双 靶点抗体高浓度眼科专用注射剂。临床前数据显示，其生物活性和动物药效均达 到 国 际 竞 品 水 平 ， 在 激 光 诱 导 的 猴 CNV （ 脉 络 膜 新 生 血 管 , choroidal neovascularization）药效模 ...

Core Viewpoint - Company received acceptance notice for clinical trial application of GB10 injection from the National Medical Products Administration, marking a significant step in the development of innovative drugs [1] Group 1: Product Development - GB10 injection is a high-concentration ophthalmic injection targeting both VEGF and Ang-2, developed by the company's wholly-owned subsidiary, Shenzhen Kexing [1] - Preclinical data indicates that GB10 injection's biological activity and animal efficacy meet international competitive standards, effectively inhibiting choroidal neovascularization in laser-induced monkey models [1] Group 2: Strategic Importance - Acceptance of the clinical trial application represents a key advancement in the company's dual-antibody research and development strategy based on its proprietary technology platform [1] - Successful future commercialization of GB10 injection could diversify the product offerings and enhance the company's market competitiveness [1]

Group 1 - In the past five trading days, a total of 196 companies were investigated by institutions, with a significant focus on companies like Jingzhida, Xinlitai, and Enhua Pharmaceutical [1] - Among the companies investigated, 29 received attention from more than 20 institutions, with Jingzhida being the most popular, attracting 138 institutions [1] - The types of institutions involved in the investigations included 171 securities companies, 118 fund companies, and 57 private equity firms, indicating a strong interest from the securities sector [1] Group 2 - In terms of capital inflow, 8 out of the 29 companies that attracted more than 20 institutions saw net capital inflows, with Dangsheng Technology receiving the highest net inflow of 293 million yuan [1] - The performance of the investigated stocks showed that 12 companies experienced price increases, with Shen Gong Co., Jingzhida, and Xinlitai leading with gains of 31.80%, 17.68%, and 15.81% respectively [2] - Conversely, 17 companies saw declines, with Han Zhong Precision, Kexing Pharmaceutical, and Gao Weida experiencing the largest drops of 13.31%, 9.84%, and 9.25% respectively [2] Group 3 - The most frequently investigated company was Binglun Environment, which was surveyed 4 times, while Hu Dian Co. and Fule New Materials were investigated 3 and 2 times respectively [1] - The detailed list of companies investigated includes various sectors such as machinery, pharmaceuticals, and electronics, highlighting a diverse interest from institutions [2][3]